Revvity, Inc. (RVTY)

Market Cap	12.60B
Revenue (ttm)	2.81B +3.4%
Net Income	237.48M -6.6%
EPS	1.99 -3.3%
Shares Out	113.38M
PE Ratio	57.00
Forward PE	21.01
Dividend	$0.28 (0.24%)
Ex-Dividend Date	Apr 17, 2026

Volume	1,453,221
Open	114.14
Previous Close	114.61
Day's Range	109.85 - 114.34
52-Week Range	81.36 - 128.29
Beta	1.06
Analysts	Buy
Price Target	113.46 (+2.1%)
Earnings Date	Feb 2, 2026

About RVTY

Revvity, Inc. provides health sciences solutions, technologies, and services. The company provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and DNA sequencing services; and instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and dise...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1937
• Employees: 11,000
• Stock Exchange: NYSE
• Ticker Symbol: RVTY
• Website: https://www.revvity.com

Financial Performance

In 2024, Revvity's revenue was $2.76 billion, an increase of 0.16% compared to the previous year's $2.75 billion. Earnings were $270.39 million, a decrease of -60.99%.

Analyst Summary

According to 14 analysts, the average rating for RVTY stock is "Buy." The 12-month stock price target is $113.46, which is an increase of 2.10% from the latest price.

Price Target

$113.46

(2.10% upside)

Analyst Consensus: Buy